Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

NCT01678976 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy

Interventions

DRUG: BIA 2-093
DRUG: Oxcarbazepine

Sponsor

Bial - Portela C S.A.